Table 1 Patient and disease characteristics

From: Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma

Characteristics R-patients (n=23) Non-R patients (n=20) P
Age, median (range) 58 (21–65) 52 (15–65) 0.61
Male/female 10/13 12/8 0.87
IPI at diagnosis
 Intermediate-high 17 16 0.39
 High 6 4  
Disease status at PBSCT
 CR 13 9 0.37
 Cru 7 8  
 PR 3 3  
Time in months to auto-PBSCT, median (range) 5.8 (4.4–8.5) 5.6 (4.6–9.8) 0.43
  1. Abbreviations: IPI=international prognostic index; NS=not significant (P>0.05); R=rituximab.